MicroWash

Executive Summary

MicroWash is a San Francisco-based medical device company that has developed a novel nasal lavage specimen collection device for upper respiratory infection (URI) testing. The device is designed to replace traditional nasal swabs, offering a more comfortable patient experience while delivering higher-sensitivity samples for PCR testing. As a 510(k)-exempt, Class I medical device, MicroWash aims to improve infectious disease preparedness and testing compliance. The company was founded in 2020 and is privately held. Although specific funding details and valuation are not publicly disclosed, the company targets a significant market opportunity in diagnostics and digital health. Its product addresses a critical pain point in URI testing: patient discomfort and sample quality variability with swabs. By improving sample collection efficiency and patient acceptance, MicroWash could increase testing rates, especially in repeat-testing scenarios such as screening programs or pandemic response. The company has the potential to become a key player in the diagnostic sample collection space, provided it successfully commercializes the device and secures adoption among healthcare providers and testing laboratories.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Exemption Clearance or Notification85% success
• Q1 2027First Clinical Study Publication Demonstrating Superiority Over Nasal Swabs60% success
• Q4 2026Strategic Partnership with a Major Diagnostic Lab or Hospital Network40% success